Some investors may welcome the Novo Nordisk Foundation’s sweeping moves to accelerate a strategy shift. Yet the speed and ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of ...

After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is ...

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.

Pharma major CEO Mike Doustdar, on Friday, 31 October 2025, said that the company has notified its employees who have been ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Pfizer today announced that it has filed a second lawsuit against Metsera, its controlling stockholders, and Novo Nordisk in the US District Court for the District of Delaware.

Danish pharma major Novo Nordisk today confirmed that it submitted an unsolicited proposal to acquire Metsera, aiming to ...

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach ...